InvestSMART

IDT Australia Limited (ASX:IDT)

ALERT: Price-sensitive ASX Announcement for IDT
Current share price for IDT : $0.041 0.009 (28.13%)+
Release
21 Jul 2026 2:18PM
Price at Release
$0.032
Full Release
download
Summary
IDT Australia Limited has announced an upgrade to its financial guidance for the fiscal year 2026 (FY26), driven by favorable trading conditions and strong operational performance. The company now expects revenue from its three verticals to increase by 16.5% year-over-year to $16.8 million, with a significant improvement in EBITDA to -$943K, compared to -$6.3M in FY25. This upgrade is attributed to strong demand for its drug manufacturing services and cost savings outpacing targets. IDT has been recognized with prestigious awards for its excellence in RNA manufacturing, reinforcing its leadership in the RNA therapeutics sector.
Key Points
  • Upgrade to FY26 financial guidance announced.
  • Revenue from three verticals expected to increase by 16.5% YOY to $16.8 million.
  • Significant improvement in EBITDA forecasted to -$943K.
  • Strong demand and cost savings driving positive outlook.
  • Recognition with RNA manufacturing excellence awards.
  • Full year results and audited accounts to be released next month.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.